



FOR IMMEDIATE RELEASE

## **Immgenuity Inc. To Present Science of IMTV014 at HIV Cure Symposium in Ghent, Belgium**

Dover, Delaware, August 11, 2023 – Immgenuity, a biotech company focused on developing innovative immunotherapies, will present a poster abstract on its lead therapeutic IMTV-014 at HIV Cure Symposium organized by the HIV Cure Research Center at the University of Ghent in Belgium on September 11 and 12, 2023.

Immgenuity’s therapeutic vaccine platform, led by IMTV-014, is based on a unique approach that harnesses the immune system to target and eliminate HIV-infected cells. The vaccine is designed to boost the immune response to the virus and induce sustained control of the virus in patients with HIV. The company’s approach is differentiated from traditional antiretroviral therapy, which requires lifelong treatment and does not provide a cure. The approach is also different from traditional therapeutic vaccines for HIV in that it uniquely addresses restoration of immune signaling.

“Our abstract titled ‘Targeting Nef as the Primary Driver of HIV Persistence and Immune Escape with a *nef* deleted Therapeutic Vaccine’, was accepted as a poster and an oral presentation at HCS and will be presented in the topic category of Immunopathogenesis and Vaccines. HCS is a globally recognized conference that brings together the finest scientists and new developments in therapeutic advancements and cure strategies for HIV/AIDS such as Dr. Steven Deeks at UCSF and Dr Franchesco Simonetti from Johns Hopkins among many other notable names. Needless to say we are excited to present our therapeutic vaccine platform at the HCS”, said Sateesh Apte, MD, CEO of Immgenuity, Inc.

The HCS Conference is a renowned international gathering of scientists, researchers, and experts in the field of HIV research and therapy. The conference provides a platform for sharing the latest scientific advancements, clinical trials, and breakthroughs in the field of cure research in HIV/AIDS.

### **About Immgenuity, Inc.**

Immgenuity, Inc. is a biotechnology company dedicated to developing innovative immunotherapy solutions to improve the lives of patients suffering from HIV. The company’s lead product candidate is IMTV014, a novel immunotherapy for HIV and NeuroAIDS, which has shown to be safe in preclinical studies. Immgenuity, Inc. is headquartered in Dover, Delaware and is led by a team of experienced biotech professionals with deep expertise in infectious diseases, immunology, virology, and drug development. For more information, visit <https://immgenuity.com>

### **About IMTV014**

Immgenuity’s immunotherapy, IMTV014 is a genetically modified HIV virus which is unable to block immune signaling like the natural HIV does. By restoring immune signaling, IMTV014 plans to activate the immune system to create a strong, viable immune response against HIV and likely lead to clearing the virus even from the sanctuary areas where the virus persists despite aggressive anti-HIV drug treatment. IMTV014 will also address various neurological and cardiovascular comorbidities caused by the virus persistence in these anatomical sanctuary areas via prolonged and elevated secretion of inflammatory cytokines. IMTV014 also has application as “salvage therapy” in the multidrug resistant population.

Contact: Media Relations: [media@immgenuity.com](mailto:media@immgenuity.com) (302) 321-5844

**Forward Looking Statements:**

This press release contains “forward-looking statements” within the meaning of federal securities law, including statements concerning the company’s outlook for 2023 and beyond; business strategies and their anticipated results; and similar statements concerning anticipated future events and expectations that are not historical facts. The forward-looking statements in this letter are subject to numerous risks and uncertainties, including the effects of economic conditions; supply and demand changes; competitive conditions in the industry; relationships with clients and distributors; the impact of government regulations; and the availability of capital to finance growth, which could cause actual results to differ materially from those expressed in or implied by the statements herein.